29.01.2015 • NewsCornelius GroupGrowthDr. Neville Prior

Cornelius Group Reorganizes for Growth

The Board of Cornelius Group, a UK-based distributor of speciality chemicals and ingredients, has announced a number of management changes to support its 2025 vision for growth.

Dr. Neville Prior, Group Chairman, said: "The Board of Cornelius has been working on our long term vision and strategy and recognizes the need to develop the structure of the company to deliver its next phase of growth."

Long term Board directors David Brown and Richard Herring remain with the Group in new non-executive director roles. David Brown is now responsible for developing the Cornelius sourcing and international business strategy working with Darren Spiby, managing director, who takes over responsibility for the overall UK & international business. Richard Herring will remain in a consulting role for the Human Resources function.

In a separate move, Joanna Stephenson joins Cornelius, as non-executive director, responsible for driving the marketing and strategic development of the Group. Joanna is a former vice president of Marketing of Linpac Group and is managing director of PHD Marketing & Strategy.

Company contact







Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.